Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monotherapy
100%
Phase I Study
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Progression-free Survival
40%
Tumor Growth
20%
Objective Response
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Disease Progression
20%
Overall Survival
20%
KRAS mutation
20%
Intravenous Infusion
20%
Cardiac Arrest
20%
Diarrhea
20%
Partial Response
20%
Renal Failure
20%
Tolerability
20%
Nave
20%
Clinical Activity
20%
Nausea
20%
Heat Shock Protein 90 (Hsp90)
20%
Side Effect Profile
20%
Treatment Duration
20%
Tumor Proliferation
20%
Serious Adverse Events
20%
Patient with Tumor
20%
Previously Treated Patients
20%
Molecular Chaperone
20%
Treatment-related
20%
Novel Inhibitors
20%
Systemic Therapy
20%
Anorexia
20%
Once-weekly
20%
Heavily Pretreated Patients
20%
QPCR Assay
20%
Crizotinib
20%
EGFR mutation
20%
Median Progression-free Survival
20%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Monotherapy
100%
Progression Free Survival
60%
Tumor Progression
40%
Epidermal Growth Factor Receptor
40%
Gene Rearrangement
40%
Anaplastic Lymphoma Kinase
40%
Adverse Event
20%
Overall Survival
20%
Diarrhea
20%
Survival Rate
20%
Heart Arrest
20%
Renal Failure
20%
Disease Exacerbation
20%
Chaperone
20%
Treatment Duration
20%
Intravenous Drug Administration
20%
Nausea
20%
Non-Small Cell Lung Cancer
20%
Systemic Therapy
20%
Heat Shock Protein 90
20%
Anorexia
20%
Tumor
20%
Diseases
20%
Crizotinib
20%
Side Effect
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Monotherapy
100%
Ganetespib
100%
Progression Free Survival
60%
Tumor Growth
40%
Epidermal Growth Factor Receptor
40%
Tolerability
40%
Anaplastic Lymphoma Kinase
40%
Disease Exacerbation
20%
Adverse Event
20%
Survival Rate
20%
Overall Survival
20%
Heart Arrest
20%
Kidney Failure
20%
Chaperone
20%
Nausea
20%
Heat Shock Protein 90
20%
Diarrhea
20%
Anorexia
20%
Diseases
20%
Crizotinib
20%
Side Effect
20%
Biochemistry, Genetics and Molecular Biology
Progression Free Survival
100%
Tumor Progression
66%
Epidermal Growth Factor Receptor
66%
Gene Rearrangement
66%
KRAS
66%
Anaplastic Lymphoma Kinase
66%
Survival Rate
33%
Heat Shock Protein
33%
Chaperone (Protein)
33%
Overall Survival
33%
Cardiac Arrest
33%
Crizotinib
33%